GlassScriptPhysician profile
Alexandra Ozder
NPI 1164047338
$1,801.37
in general payments reported to CMS, 2019-2025
11 companies · $565 in 2025
The $565 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $190 · 2023: $477 · 2024: $569 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $684.57 | 2022-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $603.03 | 2022-2025 | |
| Pfizer INC. | $136.34 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $124.32 | 2023 | Quviviq |
| Novo Nordisk INC | $55.82 | 2023-2025 | Wegovy |
| Abbott Laboratories | $51.21 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Vanda Pharmaceuticals INC. | $40.74 | 2025 | Fanapt |
| Lilly USA, LLC | $34.10 | 2024 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $30.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.62 | 2024 | Trintellix |
| Merz North America, INC. | $18.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Ozder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.